Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP328553.RAOHmNcZCiSgsEMHI28lBKfeva-VN7k0wgQRZQQAueLNM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP328553.RAOHmNcZCiSgsEMHI28lBKfeva-VN7k0wgQRZQQAueLNM130_assertion type Assertion NP328553.RAOHmNcZCiSgsEMHI28lBKfeva-VN7k0wgQRZQQAueLNM130_head.
- NP328553.RAOHmNcZCiSgsEMHI28lBKfeva-VN7k0wgQRZQQAueLNM130_assertion description "[We evaluated insulin secretory capacity with oral and intravenous glucose tolerance tests (early insulin response) and hyperglycaemic clamp (insulin secretory capacity) and the rates of whole body glucose uptake with the euglycaemic clamp, HLA-DQB1 genotypes (time-resolved fluorescence) and islet cell antibodies (ICA) (immunofluorescence) and antibodies to glutamic acid decarboxylase (GAD) (radio-immunoprecipitation) in 36 non-diabetic offspring (LADA-offspring) of patients with Type II (non-insulin-dependent) diabetes mellitus who tested positive for ICA and/or GAD antibodies during the 10-year follow-up from the diagnosis and in 19 healthy control subjects without a family history of diabetes.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP328553.RAOHmNcZCiSgsEMHI28lBKfeva-VN7k0wgQRZQQAueLNM130_provenance.
- NP328553.RAOHmNcZCiSgsEMHI28lBKfeva-VN7k0wgQRZQQAueLNM130_assertion evidence source_evidence_literature NP328553.RAOHmNcZCiSgsEMHI28lBKfeva-VN7k0wgQRZQQAueLNM130_provenance.
- NP328553.RAOHmNcZCiSgsEMHI28lBKfeva-VN7k0wgQRZQQAueLNM130_assertion SIO_000772 10663218 NP328553.RAOHmNcZCiSgsEMHI28lBKfeva-VN7k0wgQRZQQAueLNM130_provenance.
- NP328553.RAOHmNcZCiSgsEMHI28lBKfeva-VN7k0wgQRZQQAueLNM130_assertion wasDerivedFrom befree-20140225 NP328553.RAOHmNcZCiSgsEMHI28lBKfeva-VN7k0wgQRZQQAueLNM130_provenance.
- NP328553.RAOHmNcZCiSgsEMHI28lBKfeva-VN7k0wgQRZQQAueLNM130_assertion wasGeneratedBy ECO_0000203 NP328553.RAOHmNcZCiSgsEMHI28lBKfeva-VN7k0wgQRZQQAueLNM130_provenance.